Right Drug Right Patient Right Time © Copyright Clinigen Group plc. All rights reserved Shaun ChiltonGroup COO July 2015 Proactive Investor Presentation

Right Drug Right Patient Right Time © Copyright Clinigen Group plc. All rights reserved Clinigen Extends Unique Business Model MA CTS GA SP Clinigen SP uses the relationships and insights gained from late stage product withdrawals and non-launch market access programs run by GAP/MAP to identify candidates for acquisition or commercialisation Clinigen CTS / Idis CTP will benefit from Clinigen SP’s regulatory, pharmacovigilance and quality systems required as a specialty pharmaceutical company Idis Managed Access provides on-going patient access to comparator drugs following their clinical trial, benefiting from relationships in the clinical trial market gained by Clinigen CTS/CTP Idis’ Global Access meets local unlicensed supply, drug shortages, identifying commercialisation opportunities in local/regional markets 2

Right Drug Right Patient Right Time © Copyright Clinigen Group plc. All rights reserved The Enlarged Group (FY14 Financials) Clinical Trial ProcurementManaged Access DivisionGeneral Access DivisionCommercial SupplyClinical Trial ServicesGlobal Access ProgramsSpecialty Pharmaceuticals £16.5m £100.6m £32.0m £31.8m £83.6m £16.1m £26.9m Idis Revenue £180.9m Clinigen Revenue £126.6m Revenue GP% Revenue GP% 13.2% 15.4% 39.4% 1.8% 15.1% 33.5% 86.2% 17.1%Idis GP £30.9m Clinigen GP £41.2m32.5% Total Revenue £307.5m Total GP £72.1m EBITDA £39.3m GP% 23.4% EBITDA% 12.8% Clinigen EBITDA £26.8m 21.2% Idis EBITDA £12.5m 6.9% 3

Right Drug Right Patient Right Time © Copyright Clinigen Group plc. All rights reserved A More Balanced Portfolio 4 £126.6m £41.2m£72.1m £307.5m Note: Combined numbers are audited Clinigen June 14 and Idis November 14

Right Drug Right Patient Right Time © Copyright Clinigen Group plc. All rights reserved Unlicensed Medicine Market – Huge Potential General “unethical” unlicensed supply Market size estimated minimum of $5bn+++ Internet pharmacy, uncontrolled import, direct to patient, parallel import, illegal medicines. Some estimates range $8bn-$200bn Ethical on-demand unlicensed supply Market size c.$2.2bn Europe Idis dominates, RoW demand met by local wholesalers and agents. An ethical supplier can offer a compelling wider solution. Exclusive Managed Access Programs Market size c.$ m Idis and Clinigen are market leaders, a significant proportion managed in-house and some early access by CRO’s Extended Access (non launch) Early Access Mature Access 5 An ethical supply alternative needed to meet hospital pharmacist and clinician need

Right Drug Right Patient Right Time © Copyright Clinigen Group plc. All rights reserved Clinical Trial ServicesManaged AccessGlobal AccessCommercial SupplySpecialty Pharmaceuticals Opportunities £116.7m £32.0m £100.1m Global market leader position. Change charging model as Idis GP% lower. Exploit new services e.g. RWE, SSD Estimated $5bn+++ global market. Huge opportunities in pharmerging markets becoming the ethical supplier of choice, by expanding global footprint. Exploit iStore on-line offering Strengthens global market leader position. Complimentary customer list. Exploit broader BD capability. Introduce value added services 6 £31.8m £26.9m Margin dilutive, improve or discard. Valid market model for global footprint expansion, but weak commercial and pricing model, of which a detailed review will be undertaken Remain with strategy of growing from 5 to 10 products that can be revitalised. Improved by global footprint expansion. Increased acquisition opportunities from Idis MAP and On-Demand £307.5m Revenue FY14